The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Neovascular Age-related Macular Degeneration (nAMD)
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
Study of AR-14034 in Participants with Neovascular Age-Related Macular Degeneration (nAMD)
-
Northern California Retina Vitreous Associates Medical Group, Mountain View, California, United States, 94040
Retina Specialty Institute, Pensacola, Florida, United States, 32503
Retina Vitreous Associates of Florida, Saint Petersburg, Florida, United States, 33711
MidAtlantic Retina Research, Philadelphia, Pennsylvania, United States, 19107
Retina Research Institute of Texas, Abilene, Texas, United States, 79606
Medical Center Ophthalmology Associates, San Antonio, Texas, United States, 78240
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to
ALL
No
Alcon Research,
Director of Clinical Development, Alcon, STUDY_DIRECTOR, Aerie Pharmaceuticals
2027-03